- Home
- AKTX vs INTS Comparison
AKTX vs INTS Comparison
Compare AKTX & INTS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AKTX
- INTS
- Stock Information
- Founded
- AKTX N/A
- INTS 2012
- Country
- AKTX United States
- INTS United States
- Employees
- AKTX N/A
- INTS N/A
- Industry
- AKTX Biotechnology: Pharmaceutical Preparations
- INTS Biotechnology: Pharmaceutical Preparations
- Sector
- AKTX Health Care
- INTS Health Care
- Exchange
- AKTX Nasdaq
- INTS Nasdaq
- Market Cap
- AKTX 24.5M
- INTS 35.3M
- IPO Year
- AKTX N/A
- INTS 2023
- Fundamental
- Price
- AKTX $0.91
- INTS $2.35
- Analyst Decision
- AKTX
- INTS Strong Buy
- Analyst Count
- AKTX 0
- INTS 3
- Target Price
- AKTX N/A
- INTS $8.50
- AVG Volume (30 Days)
- AKTX 26.8K
- INTS 21.2K
- Earning Date
- AKTX 03-25-2025
- INTS 03-21-2025
- Dividend Yield
- AKTX N/A
- INTS N/A
- EPS Growth
- AKTX N/A
- INTS N/A
- EPS
- AKTX N/A
- INTS N/A
- Revenue
- AKTX N/A
- INTS N/A
- Revenue This Year
- AKTX N/A
- INTS N/A
- Revenue Next Year
- AKTX N/A
- INTS N/A
- P/E Ratio
- AKTX N/A
- INTS N/A
- Revenue Growth
- AKTX N/A
- INTS N/A
- 52 Week Low
- AKTX $0.85
- INTS $1.50
- 52 Week High
- AKTX $4.40
- INTS $5.78
- Technical
- Relative Strength Index (RSI)
- AKTX 39.80
- INTS 55.36
- Support Level
- AKTX $0.89
- INTS $2.18
- Resistance Level
- AKTX $1.00
- INTS $2.42
- Average True Range (ATR)
- AKTX 0.09
- INTS 0.19
- MACD
- AKTX 0.00
- INTS 0.01
- Stochastic Oscillator
- AKTX 18.85
- INTS 85.71
About AKTX Akari Therapeutics plc ADS
Akari Therapeutics PLC is a clinical stage biopharmaceutical company. It is focused on developing therapies for autoimmune and inflammatory diseases involving the complement component 5 (C5) and leukotriene B4 (LTB4) pathways. The company's pipelines include HSCT-TMA and Geographic Atrophy (GA).
About INTS Intensity Therapeutics Inc. Common stock
Intensity Therapeutics Inc is a clinical-stage biotechnology company pioneering a new immune-based approach to treat solid tumor cancers. The company leverages its DfuseRxtechnology platform to create new, proprietary drug formulations that, following direct injection, rapidly disperse throughout a tumor and diffuse therapeutic agents into cancer cells. Intensity's product candidates have the potential to induce an adaptive systemic immune response that not only attacks the injected tumor, but also non-injected tumors. Their pipeline is focused on realizing the full potential of INT230-6 in metastatic and local disease settings to help cancer patients with major unmet medical need.